ArticleBioactive materials2026
Bimetallic nanozymes with galvanic cell effects eradicate intratumoral bacteria and tumor cells to overcome drug resistance and potentiate antitumor immune responses for tumor therapy.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biointegrated Battery-Based Electroceuticals.Advanced materials (Deerfield Beach, Fla.) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumoral bacteria have attracted considerable attention as critical components of the tumor microenvironment (TME) that influence tumor initiation, progression, therapeutic efficacy, and immune responses. Conventional antibiotic approaches for eradicating intratumoral bacteria are limited by severe side effects, disruption of microbial homeostasis, and the emergence of multidrug resistance, while offering no direct tumoricidal effects. Here, we developed bimetallic Copper-Tin nanozymes (CuSn nanozymes) with a galvanic cell effect to overcome bacteria-associated challenges, overcome drug resistance, and enhance cancer therapy. The nanozymes can generate highly active electrons and metal ions at tumor sites without external stimulation, achieving massive reactive oxygen species (ROS) production and effective tumor eradication. The released electrons disrupt bacterial electron transport chains (ETC), thereby inhibiting energy synthesis and achieving potent antibacterial effects. The release of copper ions further enhances ROS-mediated antibacterial activity. Moreover, bacterial eradication promotes antitumor immune activation, further enhancing therapeutic outcomes. Using breast, endometrial, and liver cancer models, we demonstrated the broad applicability of this approach. This work not only offers a new paradigm for designing innovative bimetallic nanozymes with enhanced catalytic activity but also provides a potential therapeutic approach for simultaneously eliminating bacteria and tumors, overcoming chemoresistance, and offering effective treatment without reliance on conventional antibiotics or chemotherapeutics for microbiota-enriched tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.